Brexit draft agreement – pharma industry reacts

Brexit draft agreement – pharma industry reacts
Credit: Shutterstock.com/ nito

Responding to the announcement of the Withdrawal Agreement and political declaration on the UK’s future relationship with the EU, the Association of the British Pharmaceutical Industry welcomes an important step towards securing a Brexit deal.

The ABPI welcomed the agreement of a transition period, which will enable companies to get medicines to patients in March 2019, alongside the approach taken in the declaration on the future UK – EU relationship.

While significant contingency planning has been put in place by pharmaceutical companies to ensure that patients continue to get medicines in any Brexit scenario, the ABPI has always maintained that this would be challenging in a ‘no deal’ scenario.

Mike Thompson, CEO at the Association of the British Pharmaceutical Industry (ABPI), said: “We welcome this important step towards securing a Brexit deal.

“Agreeing a transition period will mean that our members can continue to supply medicines to patients without delay or disruption come March 2019.

“There’s much to build on. But there’s more work to be done. We are committed to working with the UK and the EU so that close cooperation on scientific research and medicines regulation are central to a future partnership agreement for the benefit of all.”